Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anifrolumab in Moderate-to-Severe Systemic Lupus Erythematosus
NCT04877691Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jun 2021
- Primary completion
- Aug 2025
- Modality
- Monoclonal Antibodies
- Countries
- 15
01
Overview
A Phase 3 trial of anifrolumab in systemic lupus erythematosus (SLE), sponsored by AstraZeneca. Started Jun 2021; status: active, not recruiting.
02
Drugs
anifrolumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT04877691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04877691.